CSL is a global biotechnology company with headquarter in Australia that develops and delivers innovative biotherapies. The company’s Research Acceleration Initiative (RAI) aims to explore partnerships on novel biotherapeutic strategies in CSL’s therapeutic areas, with funding up to USD200k per year for up to 2 years.
The 2023 RAI focuses on research proposals that align with a CSL therapeutic areas and are amenable to or include a modality. More details can be found at Gloabl RAI 2023 Scientific Flyer and Information Session Deck. Researchers who wish to apply are required to submit a non-confidential, 300 word abstract by 23 February 2023 9am HKT to Research and Innovation Office (RIO).
Please visit CSL's website for more details.